|Title:||An in vitro investigation of Aerosolised Budesonide Delivery in Simulated Adult and Paediatric Spontaneous Breathing Models using a Vibrating Mesh Nebuliser|
|Author(s):||P.J. Naughton, B. Murphy, A. O’Sullivan, M. Mac Giolla Eain, M. Joyce & R. MacLoughlin|
|Poster:||Click to view poster|
|Category:||Asthma and COPD|
|Abstract:||Aerosolised corticosteroids are commonly used in the treatment and prevention of airway inflammation associated with asthma and other respiratory illnesses. The aim of this study was to assess aerosol delivery performance of Budesonide during simulated adult and paediatric spontaneous breathing. |
A standard 2 mL dose of Budesonide (Pulmicort 0.5 mg/2 mL, Astra Zeneca, UK) was aerosolised using the Aerogen Solo (Aerogen, Ireland) in combination with the Aerogen Ultra aerosol chamber and facemask, with 2 litres per minute supplemental gas flow. A breathing simulator (Copley Scientific, UK) in combination with appropriate head models was used to generate both adult (Vt 500mL, 15 BPM, I:E 1:1) and paediatric (Vt 155 mL, 25 BPM, I:E I:2) breaths as per International Standard ISO27427.2 The mass of drug delivered to the level of the trachea was determined using UV spectrophotometry (241 nm). Five replicates were performed for each test.
Following test, the recorded tracheal doses were adult (23.36 ± 1.35 %), and paediatric (15.14 ± 1.15 %). This study confirms that high levels of Budesonide can be delivered using a vibrating mesh nebuliser. This information should inform clinicians in their approach to clinical aerosol therapy.
Conflicts of Interest:
All authors are employees of Aerogen.